Artiva rises after positive safety data for new autoimmune disease therapy

Artiva Biotherapeutics

12/11/2025 15:12

Updates

** Shares of drug developer Artiva Biotherapeutics ARTV.O rise 2% to $3.66 in early trading

** Co says its experimental cell therapy, AlloNK, showed promising safety results in early trials for patients with autoimmune diseases, including rheumatoid arthritis

** ARTV says 32 autoimmune patients got AlloNK plus anti-CD20 antibody drugs at community clinics, mostly outside hospitals, with no severe side effects

** Co says treatment clears B cells, a type of immune cell linked to several autoimmune conditions, within two weeks

** Over 150,000 U.S. patients have RA that does not respond to current medicines, ARTV says

** Including session's move, stock down ~64% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))